Circulating plasma miRNA-21 as a superior biomarker compared to CA 15-3: Assessment in healthy age matched subjects and different stage of breast cancer patients

Merlyna Savitri, Ugroseno Yudho Bintoro, Made Putra Sedana, Muhammad Noor Diansyah, Pradana Zaky Romadhon, Putu Niken Ayu Amrita, Andi Yasmin Wijaya, Winona May Hendrata, Ami Ashariati Prayogo

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

BACKGROUND: Carbohydrate antigens 15-3 (CA 15-3) is a conventional tumor marker in breast cancer, with low sensitivity and specificity. MicroRNA (miRNA)-21 showed its stability in circulation and could serve as powerful biomarker. The aim of this study was to evaluate miRNA-21 as breast cancer biomarker compared to CA 15-3 in Indonesian population. METHODS: Circulating plasma miRNA-21 expression was measured using qRT-PCR in 49 patients at various stages of breast cancer and 16 healthy controls. The relative expression value of miRNA-21 was calculated using 2-ΔΔCt. Meanwhile, CA 15-3 was quantified using electrochemiluminescence immunoassay (ECLIA) methods. The results of miRNA-21 and CA 15-3 plasma circulating expression were compared with controls at each stage and between stages of breast cancer. RESULTS: CA 15-3 median level in breast cancer group was 1.60 times higher compared to control group (p=0.019), 21.00 m/mL and 13.05 m/mL, respectively. Median miRNA-21 expression in breast cancer group was elevated 4.92 folds compared to control group (p=0.001), 4.43 and 0.90, respectively. There was no significant difference of CA 15-3 level between controls and all stages of breast cancer group. CA 15-3 cut-off value was 15.05 m/mL (p=0.016) with 59.2% sensitivity and 62.5% specificity. Meanwhile, there was a significant difference of miRNA-21 expression between controls and most stages of breast cancer group. Circulating miRNA-21 expression cut-off value was 2.07 (p=0.000) with 91.8% sensitivity and 87.5% specificity. CONCLUSION: Circulating miRNA-21 expression and CA 15-3 levels were significantly increased in breast cancer group compared to control group. The miRNA-21 expression increased consistently with breast cancer stage progression. miRNA-21 could serve as superior biomarker compared to CA 15-3.

Original languageEnglish
Pages (from-to)157-164
Number of pages8
JournalIndonesian Biomedical Journal
Volume12
Issue number2
DOIs
Publication statusPublished - 1 Jun 2020

Keywords

  • Biomarker
  • Breast cancer
  • Circulating plasma
  • Liquid biopsy
  • MiRNA-21

Fingerprint

Dive into the research topics of 'Circulating plasma miRNA-21 as a superior biomarker compared to CA 15-3: Assessment in healthy age matched subjects and different stage of breast cancer patients'. Together they form a unique fingerprint.

Cite this